Vanguard Group Inc Viridian Therapeutics, Inc.\De Transaction History

Vanguard Group Inc

$6.44 Trillion
Q3 2025

A detailed history of Vanguard Group Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Vanguard Group Inc holds 4,331,983 shares of VRDN stock, worth $125 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,331,983

Previous 4,508,508 3.92%

Holding current value

$125 Million

Previous $63 Million 47.84%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 07, 2025	SELL	$14.5 - $21.61 $2.56 Million - $3.81 Million	-176,525 Reduced 3.92%	4,331,983 $93.2 Million
Q2 2025 Aug 11, 2025	SELL	$11.02 - $16.09 $601,603 - $878,385	-54,592 Reduced 1.2%	4,508,508 $63 Million
Q1 2025 May 09, 2025	SELL	$13.48 - $20.91 $430,672 - $668,053	-31,949 Reduced 0.7%	4,563,100 $61.5 Million
Q4 2024 Feb 11, 2025	BUY	$17.85 - $25.71 $3.12 Million - $4.5 Million	174,952 Added 3.96%	4,595,049 $88.1 Million
Q3 2024 Nov 13, 2024	BUY	$12.16 - $23.33 $13.1 Million - $25.1 Million	1,074,366 Added 32.11%	4,420,097 $101 Million
Q2 2024 Aug 13, 2024	BUY	$11.6 - $17.26 $1.29 Million - $1.92 Million	111,452 Added 3.45%	3,345,731 $43.5 Million
Q1 2024 May 10, 2024	BUY	$17.09 - $23.82 $3.99 Million - $5.56 Million	233,331 Added 7.78%	3,234,279 $56.6 Million
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $6.15 Million - $12.4 Million	552,933 Added 22.59%	3,000,948 $65.4 Million
Q3 2023 Nov 14, 2023	SELL	$15.16 - $24.7 $2.25 Million - $3.67 Million	-148,629 Reduced 5.72%	2,448,015 $37.6 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $10.5 Million - $13.8 Million	466,411 Added 21.89%	2,596,644 $61.8 Million
Q1 2023 May 15, 2023	BUY	$25.04 - $37.6 $381,584 - $572,986	15,239 Added 0.72%	2,130,233 $54.2 Million
Q4 2022 Feb 10, 2023	BUY	$18.78 - $29.74 $4.85 Million - $7.68 Million	258,194 Added 13.91%	2,114,994 $61.8 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $4.77 Million - $11.4 Million	445,898 Added 31.6%	1,856,800 $38.1 Million
Q2 2022 Aug 12, 2022	BUY	$9.55 - $19.0 $4.49 Million - $8.94 Million	470,325 Added 50.0%	1,410,902 $16.3 Million
Q1 2022 May 13, 2022	BUY	$16.79 - $20.88 $250,187 - $311,132	14,901 Added 1.61%	940,577 $17.4 Million
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $7.26 Million - $9.97 Million	463,764 Added 100.4%	925,676 $18.3 Million
Q3 2021 Nov 12, 2021	BUY	$10.69 - $18.2 $1.15 Million - $1.96 Million	107,846 Added 30.46%	461,912 $7.6 Million
Q2 2021 Aug 13, 2021	BUY	$14.34 - $18.67 $5.08 Million - $6.61 Million	354,066 New	354,066 $6.48 Million

Others Institutions Holding VRDN

# of Institutions

185

Shares Held

81.8M

Call Options Held

39.6K

Put Options Held

94.3K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $1.15B
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Viridian Therapeutics, Inc.\De Transaction History